PROFILE |
 |
MacroChem is developing transdermal drug-delivery systems, which allow drugs to be absorbed through the skin via creams, gels, patches, and the like. MacroChem is trying to attract business partners by applying its SEPA (Soft Enhancer of Percutaneous Absorption) system to FDA-approved drugs. The company is testing its system's use with drugs used to treat impotence (Topiglan), arthritis pain (Benefen), testosterone deficiency, and skin conditions. MacroChem has also developed MacroDerm, a delivery system with potential applications in cosmetics and other topical products, such as moisturizers, sunscreens, and insect repellents.
COMPETITION |
 |
Cygnus, Inc. (CYGN)
Elan Corporation, plc (ELN)
Novartis AG (NVS)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.60
1-Yr. Sales Growth: 20.0%
Employees: 30
Revenue per employee: $20,000.00
KEY PEOPLE |
 |
Bernard R. Patriacca
CFO
CONTACT INFO |
 |
110 Hartwell Ave.
Lexington, MA 02421
US
Phone: 781-862-4003
Fax: 781-862-4338
Online: Web Site
|